Novartis shelved a Phase II program it was testing for obesity-related diseases after finding a lack of efficacy, the pharma giant disclosed Tuesday in its second-quarter earnings.
The termination of MBL949 — which the company said was a GDF-15 agonist — was one of two cuts Novartis made since the last quarterly update. The other was NIS793 in metastatic pancreatic ductal adenocarcinoma, “based on benefit-risk assessment.” A Phase II study of NIS793 in colorectal cancer will continue.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters